Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Graves

Physician Assistant, Medical Muskogee, OK Physician Assistant

NPI 1407120066 CMS profile 10957031

333 S 38Th St Ste E, Muskogee, OK 74401

Open in the dashboard

General payments

$12,658

327 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Graves of Muskogee, OK is reported in the CMS Open Payments database as having received $12,658 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,886 83
2024 General $5,826 59
2023 General $1,360 51
2022 General $1,577 55
2021 General $2,008 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Graves
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jessica Graves were reported at $1,886. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jessica Graves Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,008 $156 $41–$563 $132
2022 $1,577 $185 $55–$649 $149
2023 $1,360 $199 $58–$717 $160
2024 $5,826 $206 $62–$740 $164
2025 $1,886 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Organogenesis Inc. $4,392 28 payments
  2. E.R. Squibb & Sons, L.L.C. $1,520 27 payments
  3. Pfizer Inc. $1,127 39 payments
  4. AbbVie, Inc. $1,094 27 payments
  5. Regeneron Healthcare Solutions, Inc. $1,028 48 payments
  6. Lilly USA, LLC $716 23 payments
  7. Novartis Pharmaceuticals Corporation $562 27 payments
  8. Janssen Biotech, Inc. $324 17 payments
  9. Amgen Inc. $257 13 payments
  10. UCB, Inc. $228 17 payments
  11. Other $1,411 61 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,525 316 payments
  2. Consulting Fee $2,585 1 payment
  3. Travel and Lodging $1,143 3 payments
  4. Education $404 7 payments
Products named General payments · program years 2021–2025
  1. PURAPLY WOUND MATRIX $3,841 5 payments
  2. SOTYKTU $1,434 26 payments
  3. CIBINQO $766 28 payments
  4. DUPIXENT $737 35 payments
  5. LITFULO $716 24 payments
  6. SKYRIZI $611 18 payments
  7. TALTZ $524 21 payments
  8. TREMFYA $433 17 payments
  9. RINVOQ $344 6 payments
  10. Puraply $275 12 payments
  11. Other $3,650 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,147

Median for Physician Assistant: 241

Drug cost

$551,807

Median for Physician Assistant: $4,110

Branded share of claims

11.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 14 $216,290
Dupixent Pen Dupilumab Brand 50 $208,062
Otezla Apremilast Brand 15 $73,961
Fluorouracil Generic 156 $11,812
Pimecrolimus Generic 25 $10,217
Tacrolimus Generic 61 $7,146
Calcipotriene Generic 53 $5,519
Betamethasone Dipropionate Generic 75 $3,698
Clobetasol Propionate Generic 93 $3,304
Ketoconazole Generic 146 $2,989

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$373,169

Of which drugs: $188,768

Medicare patients

625

Average age 73

Services billed

3,841

358 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 36%
Ischemic heart disease 28%
Depression 23%
Chronic kidney disease 21%
Heart failure 18%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Novachor, per square centimeter Q4194 Office 11 165 $127,360
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 32 68 $21,064

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $902
$902 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $244
$244 50 —
Zoryve
  • Arcutis Biotherapeutics, Inc. $86
$86 — —
Bimzelx
  • UCB, Inc. $55
$55 — —
CIBINQO
  • PFIZER INC. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record